Latest News

After over four years of strong returns, the stock market looks pricey based on some closely watched metrics.

Dreams disruption and Mattress Firm expansion shape the quarter.

BCE is yielding a very generous 5.2%, as the company's telecom business improves and long-term investments drive growth.

Learn how Thomson Reuters recovered from a 62% dip and what the future holds for its major revenue segments.

Hardware cost cuts let Peloton launch a treadmill $1,000 cheaper, while its enterprise channel continues to expand beyond the home.

Data center demand and a record EBITDA quarter shaped the results.

Intact reported $660 million in pre-tax catastrophe losses during the quarter, which dragged its net operating income per share lower.

Enbridge starts investors off with a near 5.9% dividend that can continue to grow with a steady growth profile.

Students are demanding a higher return on their investments.

AMD is still growing and is optimistic about the fourth quarter, despite recent market noise about the AI trade.

Management's push, from cutting costs to squeezing more output from existing resources, could determine whether margin gains last through the cycle.

BCE (TSX:BCE) could be a huge dividend value winner as the stock markets correct and potentially flirt with a bear market.

A $150,000 starting target can support a $6,000 annual TFSA income goal without requiring an extreme yield.

Clover Health Investments (NASDAQ:CLOV) expects another year of strong membership growth in 2027, aided by a competitor’s exit from its core New Jersey market and what it sees as favorable positioning for its Medicare Advantage plans, Chief Financial Officer Clay Thornton said. Thornton, recently a

OraSure Technologies (NASDAQ:OSUR) reported 14% year-over-year revenue growth in the third quarter of 2026, but pushed back its target for operating cash flow breakeven as the timing of several product opportunities shifted. The diagnostics and sample collection company now expects to reach operati

Lucid Group (NASDAQ:LCID) reduced its free cash outflow by 30% in the third quarter of 2026 as the electric vehicle maker cut production, sold vehicles from inventory and continued a broader cost-reduction program. The company reported revenue of $350 million, up 4% from a year earlier, and an adju

Hallador Energy (NASDAQ:HNRG) reported a third-quarter loss as lower coal sales and higher purchased-power costs weighed on results, while executives said they were working toward a year-end investment decision on the Turtle Creek gas power project. The company reported a net loss of $4.5 million f

Paysign (NASDAQ:PAYS) reported record third-quarter revenue, operating income and adjusted EBITDA as growth in its patient affordability business more than offset slower growth in plasma payment processing. Revenue rose 42.6% from a year earlier to $30.8 million, while net income climbed to $6.7 mi

iHeartMedia (NASDAQ:IHRT) reported third-quarter revenue and adjusted earnings below its guidance as weakness in its broadcast radio business outweighed growth in podcasting and digital audio. Revenue rose 3.3% from a year earlier to $1.03 billion, below the company’s forecast for mid-single-digit

Kaltura (NASDAQ:KLTR) reported record third-quarter revenue and raised its full-year outlook for the third time in 2026, as new subscription bookings more than doubled from the prior quarter and transactions involving its artificial intelligence products increased. Revenue for the quarter ended Sep

MARA (NASDAQ:MARA) reported a sharp rise in third-quarter profit despite lower revenue, as gains in the value of its Bitcoin holdings boosted results. The company also outlined plans to expand its power portfolio and convert sites into artificial intelligence and high-performance computing infrastru

AST SpaceMobile (NASDAQ:ASTS) reported $42.3 million in third-quarter revenue and reiterated its full-year 2026 revenue forecast, as it prepares to activate intermittent satellite service in the United States and other key markets before year-end. The company also outlined plans to build its own re

Coherus Oncology (NASDAQ:CHRS) plans to cut approximately 30% of its workforce and focus development of its experimental drug tagmokitug on esophageal cancer as it seeks to reduce spending and grow sales of its cancer treatment LOQTORZI. On its third-quarter 2026 earnings call, management said the

Definium Therapeutics (NASDAQ:DFTX) plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized anxiety disorder and major depressive disorder, executives said on the company’s

Compute cost discipline, not just user growth, is what lets Doximity scale AI without eroding margins as usage climbs.